Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life Sciences | GenomeWeb

This story originally ran on July 27 and has been updated to include additional comments.

By Tony Fong

Agilent Technologies continued to bet on the life-science sector on Monday, announcing it plans to spend $1.5 billion to purchase instrument and vacuum company Varian.

From a proteomics perspective, the purchase is not expected to have a profound effect on Agilent, even though Varian has a fleet of LC/MS and Fourier transform mass specs that have use in proteomics and protein analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.